Dental floss

Information

  • Patent Grant
  • 9888988
  • Patent Number
    9,888,988
  • Date Filed
    Friday, February 6, 2009
    15 years ago
  • Date Issued
    Tuesday, February 13, 2018
    6 years ago
Abstract
The present invention is directed to a dental floss comprising a basic amino acid or salt thereof.
Description
BACKGROUND OF THE INVENTION

The use of dental floss and other interdental cleaners are an important part of dental hygiene, and are used to remove plaque ad other particulate from between the teeth and under the gum line, e.g., areas in the mouth where a toothbrush cannot reach. Frequently, these are the initiation sites of tooth decay, especially if not cleaned regularly. However, even with routine maintenance, caries and gingivitis still develop in these areas. Thus, there is a continuing need to develop more effective dental flosses.


While it is recommended that people floss their teeth at least daily, the reality is that few people floss as often as recommended. Thus there is a need for more effective dental floss compositions for use by occasional flossers.


SUMMARY OF THE INVENTION

It has been discovered that basic amino acids provide beneficial effects in inhibiting bacterial attachment, promoting remineralization of the teeth, reducing the incidence of cavities and dentinal hypersensitivity, and inhibiting cariostatic bacteria in favor of arginolytic bacteria.


The present invention provides a denial floss in combination or association with a composition comprising a basic amino acid or salt thereof, e.g., arginine, arginine bicarbonate, arginine hydrochloride, or arginine phosphate. The basic amino acid or salt may be coated onto the floss, or impregnated within the floss matrix, or the dental floss may be dispensed using a package wherein the floss is stored or dispensed via a chamber comprising a composition comprising a basic amino acid, e.g., any of compositions 1.1-1.15 below.


The invention thus includes a dental floss in combination or association with (e.g., coated or impregnated with) a composition (Composition 1.0) comprising a basic amino acid or salt thereof, e.g, a dental floss in combination or association with any of the following Compositions:

  • 1.1. Composition 1.0 wherein the basic amino acid is arginine, lysine, citrullene, ornithine, creatine, histidine, diaminobutanoic acid, diaminoproprionic acid, salts thereof and/or combinations thereof.
  • 1.2. Composition 1.0 or 1.1 wherein the basic amino acid has the L-configuration.
  • 1.3. Any of the preceding compositions is provided in the form of a salt of a di- or tri-peptide comprising the basic amino acid.
  • 1.4. Any of the preceding compositions wherein the basic amino acid is arginine.
  • 1.5. Any of the preceding compositions wherein the basic amino acid is L-arginine.
  • 1.6. Any of the preceding compositions comprising a physiologically acceptable salt of a basic amino acid.
  • 1.7. Any of the preceding compositions wherein the salt of the basic amino acid is a carbonate.
  • 1.8. Any of the preceding compositions wherein the salt of the basic amino acid is a bicarbonate.
  • 1.9. Any of the preceding compositions wherein the basic amino acid salt is arginine bicarbonate.
  • 1.10. Any of the preceding compositions further comprising fluoride, or a fluoride ion source.
  • 1.11. Any of the preceding compositions comprising a fluoride ion source selected from stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluoride, ammonium fluoride, and combinations thereof.
  • 1.12. Any of the preceding compositions further comprising an antiseptic or antimicrobial.
  • 1.13. Any of the preceding compositions further comprising an antibacterial agent selected from triclosan, herbal extracts and essential oils (e.g., rosemary extract, tea extract, magnolia extract, thymol, menthol, eucalyptol, geraniol, carvacrol, citral, hinokitol, catechol, methyl salicylate, epigallocatechin gallate, epigallocatechin, gallic acid, miswak extract, sea-buckthorn extract, propolis), bisguanide antiseptics (e.g., chlorhexidine, alexidine or octenidine), quaternary ammonium compounds (e.g., cetylpyridinium chloride (CPC), benzalkonium chloride, tetradecylpyridinium chloride (TPC), N-tetradecyl-4-ethylpyridinium chloride (TDEPC)), phenolic antiseptics, hexetidine, octenidine, sanguinarine, povidone iodine, delmopinol, salifluor, metal ions (e.g., zinc salts, for example, zinc citrate, stannous salts, copper salts, iron salts), sanguinarine, propolis and oxygenating agents (e.g., hydrogen peroxide, buffered sodium peroxyborate or peroxycarbonate), phthalic acid and its salts, monoperthalic acid and its salts and esters, ascorbyl stearate, oleoyl sarcosine, alkyl sulfate, dioctyl sulfosuccinate, salicylanilide, domiphen bromide, delmopinol, octapinol and other piperidino derivatives, nicin preparations, chlorite salts; and mixtures of any of the foregoing.
  • 1.14. Any of the preceding compositions further comprising additional ingredients selected from analgesic agents, anti-inflammatory agents, coagulants, astringents, vitamins, and combinations thereof.
  • 1.15. Any of the preceding compositions further comprising binders, waxes or carriers.


The present invention further comprises a package for storing or dispensing dental floss comprising a chamber containing a basic amino acid, wherein the floss is exposed to the basic amino acid during storage or dispensing, e.g., wherein the chamber contains a composition comprising a basic amino acid, e.g., a composition according to any of compositions 1.0-1.15.


The present invention also encompasses method 2.0, a method to (i) reduce or inhibit formation of dental caries, (ii) reduce, repair or inhibit pre-carious lesions of the enamel, e.g., as detected by quantitative light-induced fluorescence (QLF) or electrical caries measurement (ECM), (iii) reduce or inhibit demineralization and promote remineralization of the teeth, (iv) reduce hypersensitivity of the teeth, (v) reduce or inhibit gingivitis, (vi) promote healing of sores or cuts in the mouth, (vii) reduce levels of acid producing bacteria, (viii) to increase relative levels of arginoiytic bacteria, (ix) inhibit microbial biofilm formation in the oral cavity, (x) raise and/or maintain plaque pH at levels of at least pH 5.5, (xi) reduce plaque accumulation, (xii) clean the teeth and oral cavity, (xiii) immunize the teeth against cariogenic bacteria, and/or (xiv) reduce erosion, (xv) enhance systemic health, and/or (xvi) treat or inhibit dry mouth, the method comprising flossing the teeth or other surfaces of the oral cavity of a patient in need thereof with a dental floss in combination or association with a basic amino acid in free or salt form (e.g., in combination or association with any of Compositions 1.0-1.15 as hereinbefore described.


Other embodiments of the present invention will be apparent to one of skill in the art.







DETAILED DESCRIPTION OF THE INVENTION

Without intending to be bound by a particular theory, it is believed that basic amino acids in the oral cavity are metabolized by certain types of bacteria, e.g., S. sanguis which are not cariogenic and which compete with cariogenic bacteria such as S. mutans, for position on the teeth and in the oral cavity. The arginolytic bacteria can use arginine and other basic amino acids to produce ammonia, thereby raising the pH of their environment, while cariogenic bacteria metabolize sugar to produce lactic acid, which tends to lower the plaque pH and demineralize the teeth, ultimately leading to cavities. It is believed that use of a Composition of the Invention may lead to a relative increase in the arginolytic bacteria and a relative decrease in the cariogenic bacteria, resulting in a higher plaque pH and a corresponding reduction in the cavitation process.


The basic amino acids which can be used in the compositions of the present the invention include not only naturally occurring basic amino acids, such as arginine, lysine, and histidine, but also any basic amino acids having a carboxyl group and an amino group in the molecule. Accordingly, basic amino acids include, but are not limited to, arginine, lysine, citrullene, ornithine, creatine, histidine, diaminobutanoic acid, diaminoproprionic acid, salts thereof or combinations thereof. In a particular embodiment, the basic amino acids are selected from arginine, citrullene, and ornithine, preferably, arginine, for example, 1-arginine.


The compositions of the invention are used in the mouth, so salts for use in the present invention should be safe for such use, in the amounts and concentrations provided. Suitable salts include salts known in the art to be pharmaceutically acceptable salts are generally considered to be physiologically acceptable in the amounts and concentrations provided. Physiologically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic acids or bases, for example acid addition salts formed by acids which form a physiological acceptable anion, e.g., hydrochloride or bromide salt, and base addition salts formed by bases which form a physiologically acceptable cation, for example those derived from alkali metals such as potassium and sodium or alkaline earth metals such as calcium and magnesium. Physiologically acceptable salts may be obtained using standard procedures known in the art, for example, by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. A preferred salt is a bicarbonate, e.g., arginine bicarbonate.


Methods of manufacturing dental floss are well known in the art. For example, dental floss may be produced from nylon, as nylon salt is polymerized and the resulting polymer is pumped or extruded to form monofilaments. The filaments are allowed to harden, and then combined to form a strand of floss. Dental floss may be produced from polytetrafluoroethylene (PTFE or Teflon®), polypropylene, polyethylene, styrene butadyene copolymers, combination of them. The polymer is melted and extruded into thin strands. See also U.S. Pat. No. 6,270,890, the contents of which are herein incorporated by reference.


In one embodiment, resin, e.g., nylon or PTFE, is mixed with a basic amino acid, or a salt thereof, and extruded to form a filament (e.g., in the case of nylon) which are twisted to form the floss, or formed into a single ribbon of floss (e.g., in the case of PTFE). It should be understood that some of the basic amino acid or salt will be disposed near the surface of the floss, and will be exposed and released when the dental floss is used. In one embodiment, the floss has a denier of about 450 to about 1350. In another embodiment the dernier of the floss is from about 100 to about 900.


Method for coating dental floss is also known in the art. In one embodiment of the present invention, the dental floss is treated in an emulsion bath comprising arginine or a pharmaceutically acceptable salt thereof. The emulsion bath may optionally contain one or more waxes, which adhere to the floss, and thereby cause the arginine to adhere to the floss. In another embodiment, a dental floss comprising a non-PTFE fiber is coated with a first and a second coating overlaying the first coating. The first coating is a nylon bonding coating, and the second coating is a wax or polymer, e.g., such as polyvinyl alcohol, polyvinyl acetate, etc, in combination or association with a basic amino acid or salt thereof. See e.g., U.S. Pat. No. 6,289,904, herein incorporated by reference.


The floss may be in the form of a single ribbon (e.g., a Teflon® or polyethylene ribbon). Alternatively, it may be bundle of thin filaments, e.g., nylon filaments. The number of filaments will be from about 2 to about 300, e.g., from about 2 to about 200, depending on the denier of the filaments. The filaments are twisted with about 1 to 5 twists per inch to form the floss. The twisting provides integrity of the floss on the spool and during subsequent handling. However, when used the filaments will spread out and splay against tooth surfaces. The floss may also be formed of interlocking fibers, e.g., as in the case Oral-B Ultra Floss™. In any case the final floss product is preferably of a thickness that allows it to fit between the teeth. The floss may be coated with a wax. Where multiple filaments are used, the coating may applied before or after twisting, preferably after twisting. Other additives may be applied to a wax coated floss after the wax coating. The flavor can be applied as a liquid or a solid. It is preferred to use a spray dried solid. Likewise, the various other additives can be applied as a liquid or a solid. When applied as a liquid the floss is dried prior to being wound onto a spool. The drying can be by radiant drying or air drying. After drying, the floss is wound onto a spool.


Denial floss is commonly supplied in plastic dispensers that contain 10 to 50 meters of floss. The dispenser typically has a small protected blade used to sever the floss when a desired amount is pulled out.


In one embodiment, of the present invention, a denial floss dispenser is provided which contains a basic amino acid, salt, or solution thereof is disposed within the container and in contact with the floss. As the floss is stored or as a user pulls out a desired amount of floss, the floss comes in contact with the basic amino acid, salt, or solution, thereby coating the floss.


Various devices have been developed to aid a user in flossing their teeth, especially when flossing of the particular tooth is difficult or awkward. Such devices are shaped like wands to hold the floss. The present invention contemplates the use basic amino acids and their salts in combination with such devices. Additionally, dental floss that do not contain a basic amino acid or salt and retained on such wands may be dipped into a basic amino acid, salt, or solution thereof to take advantage of the present invention.


In one embodiment of the present invention, the dental floss may optionally include fluoride, or a fluoride ion source. A wide variety of fluoride ion-yielding materials can be employed as sources of soluble fluoride in the present compositions. Examples of suitable fluoride ion-yielding materials are found in U.S. Pat. No. 3,535,421, to Briner et al.; U.S. Pat. No. 4,885,155, to Parran, Jr. et al. and U.S. Pat. No. 3,678,154, to Widder et al., incorporated herein by reference. Representative fluoride ion sources include, but are not limited to, stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluoride, ammonium fluoride, and combinations thereof. In certain embodiments the fluoride ion source includes stannous fluoride, sodium fluoride, sodium monofluorophosphate as well as mixtures thereof.


The dental floss of the present invention may also comprise abrasive particles, e.g., aluminium oxide, small particle silica, or other abrasive or polishing particles. See e.g., U.S. Pat. No. 6,453,912, incorporated herein by reference.


The dental floss of the present invention may also comprise an antiseptic or antimicrobial selected from triclosan, herbal extracts and essential oils (e.g. rosemary extract, thymol, menthol, eucalyptol, methyl salicylate), bisguanide antiseptics (e.g., chlorhexidine, alexidine or octenidine), quaternary ammonium compounds (e.g., cetylpyridinium chloride), phenolic antiseptics, hexetidine, povidone iodine, delmopinol, salifluor, metal ions (e.g., zinc salts, for example, zinc citrate), sanguinarine, propolis, and combinations thereof to further aid in the beneficial effects of the basic amino acid.


As use of dental floss may cause discomfort or bleeding during or after use, it may optionally comprise analgesic agents, anti-inflammatory agents, coagulants, vitamins, and combinations thereof.

Claims
  • 1. A dental floss consisting of a polymer; and a composition consisting of arginine or a physiologically acceptable salt of arginine, wherein the polymer consists of nylon and the polymer is coated or impregnated with said composition; andthe dental floss has a denier in the range selected from the group consisting of about 450 to about 1350 and about 100 to about 900.
  • 2. The floss of claim 1 wherein the physiologically acceptable salt of arginine is arginine bicarbonate.
Parent Case Info

This application claims the benefit of U.S. Patent Application Ser. No. 61/027,436 filed Feb. 8, 2008, the contents of which application is incorporated herein, by reference.

PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/US2009/033305 2/6/2009 WO 00 8/9/2010
Publishing Document Publishing Date Country Kind
WO2009/100276 8/13/2009 WO A
US Referenced Citations (81)
Number Name Date Kind
2667443 Ashton Jan 1954 A
3535421 Briner et al. Oct 1970 A
3678154 Widder et al. Jul 1972 A
3925543 Donohue Dec 1975 A
3932605 Vit Jan 1976 A
3932608 Anderson et al. Jan 1976 A
3943241 Anderson et al. Mar 1976 A
3988434 Schole et al. Oct 1976 A
4011309 Lutz Mar 1977 A
4019522 Elbreder Apr 1977 A
4022880 Vinson et al. May 1977 A
4025616 Haefele May 1977 A
4042680 Muhler et al. Aug 1977 A
4064138 Saari et al. Dec 1977 A
4100269 Pader Jul 1978 A
4108979 Muhler et al. Aug 1978 A
4108981 Muhler et al. Aug 1978 A
4146607 Ritchey Mar 1979 A
4154813 Kleinberg May 1979 A
4160821 Sipos Jul 1979 A
2772205 King Feb 1980 A
4216961 Curtis et al. Jul 1980 A
4225579 Kleinberg Sep 1980 A
4259316 Nakashima et al. Mar 1981 A
4269822 Pellico et al. May 1981 A
4305928 Harvey Dec 1981 A
4335102 Nakashima et al. Jun 1982 A
4339432 Ritchey et al. Jul 1982 A
RE31181 Kleinberg et al. Mar 1983 E
4466954 Ichikawa et al. Aug 1984 A
4477429 Silbering et al. Oct 1984 A
4528181 Morton et al. Jul 1985 A
4532124 Pearce Jul 1985 A
4538990 Pashley Sep 1985 A
4645662 Nakashima et al. Feb 1987 A
4656031 Lane et al. Apr 1987 A
4725576 Pollock et al. Feb 1988 A
4885155 Parran, Jr. et al. Dec 1989 A
4997640 Bird et al. Mar 1991 A
5096700 Siebel et al. Mar 1992 A
5226434 Britton et al. Jul 1993 A
5266306 Ohtsuki et al. Nov 1993 A
5292526 Gaffar et al. Mar 1994 A
5330357 Keller Jul 1994 A
5286480 Boggs et al. Aug 1994 A
5334617 Ulrich et al. Dec 1994 A
5370865 Yamagishi et al. Dec 1994 A
5560377 Donovan Oct 1996 A
5639795 Friedman Jun 1997 A
5693795 Friedman et al. Jun 1997 A
5747004 Giani et al. May 1998 A
5762911 Kleinberg et al. Jun 1998 A
5829458 Chodorow Nov 1998 A
5906811 Hersh May 1999 A
5922346 Hersh Jul 1999 A
5997301 Linden Dec 1999 A
6166102 Ahn et al. Dec 2000 A
6217851 Kleinberg et al. Apr 2001 B1
6270879 Flautt et al. Aug 2001 B1
6270890 Curtis et al. Aug 2001 B1
6289904 Suhonen et al. Sep 2001 B1
6436370 Kleinberg et al. Aug 2002 B1
6453912 Antler Sep 2002 B1
6488961 Robinson et al. Dec 2002 B1
6524558 Kleinberg et al. Feb 2003 B2
6524588 Kleinberg et al. Feb 2003 B1
6558654 McLaughlin May 2003 B2
6616933 Breton et al. Sep 2003 B1
6648644 Flemmig et al. Nov 2003 B1
6805883 Chevaus et al. Oct 2004 B2
7083411 Flemmig et al. Aug 2006 B2
20020081360 Burgard et al. Jun 2002 A1
20050006263 Tsaur Jan 2005 A1
20050048005 Stockel Mar 2005 A1
20050266382 Soler et al. Dec 2005 A1
20060246398 Groll et al. Nov 2006 A1
20070116831 Prakash et al. May 2007 A1
20070119475 Hudnall et al. May 2007 A1
20070154863 Cai et al. Jul 2007 A1
20070254067 Ha Nov 2007 A1
20070286820 Prencipe et al. Dec 2007 A1
Foreign Referenced Citations (30)
Number Date Country
611544 Oct 1989 AU
688136 Mar 1998 AU
703797 Apr 1999 AU
708978 Aug 1999 AU
737982 Sep 2001 AU
2259630 Jan 1998 CA
485616 May 1992 EP
680250 Oct 1952 GB
63-288152 Nov 1988 JP
4036230 Feb 1992 JP
6-287126 Oct 1994 JP
H07-100153 Apr 1995 JP
7258053 Oct 1995 JP
H07-258053 Oct 1995 JP
2001-500405 Jan 2001 JP
2001-504083 Mar 2001 JP
2003-225250 Aug 2003 JP
2005015435 Jan 2005 JP
2006-206581 Aug 2006 JP
2007-506779 Mar 2007 JP
2020896 Oct 1994 RU
2039535 Jul 1995 RU
504379 Oct 2002 TW
200509977 Mar 2005 TW
200640532 Dec 2006 TW
200744702 Dec 2007 TW
WO2000078270 Dec 2000 WO
WO 03090639 Nov 2003 WO
WO 2004113050 Dec 2004 WO
WO2009100267 Aug 2009 WO
Non-Patent Literature Citations (11)
Entry
US 5,989,525, 11/1999, Kleinberg et al. (withdrawn)
Machado et al. CaviStat Confection Inhibition of Caries in Posterior Teeth, Abstract, 83rd Session of the American Association for Dental Research, Mar. 21-24, (2007), New Orleans, LA.
Chatterjee et al,. Bacterial Acidification and CaviStat Alkalinization of Occlusal Fissure pH, Abstract, 83rd Session of the American Association for Dental Research, Mar. 9-12, (2005), Baltimore, MD.
Kleinberg I., A Mixed-Bacteria Ecological Approach to Understanding the Role of the Oral Bacteria in Dental Caries Causation: An Alternative to Streptococcus Mutans and the Specific-Plaque Hypothesis, Crit. Rev. Oral Biol. Med,. 12(2): 108-125 (2002).
Kleinberg I., A New Salvia-Based Anticaries Composition, Dentistry Today, vol. 18, No. 2, Feb. 1999.
Acevedo et al., “The Inhibitory effect of an arginine bicarbonate/calcium carbonate (CaviStat)-containing dentifrice on the develpoment of dental caries in Venezuelean school children”, The Journal of clinical Dentistry, 2005, v.16, No. 3,pp. 63-70, ISSN 0895-8831.
Packaging with ingredient list for DenClude® (launched Dec. 2004).
Packaging with ingredient list for ProClude® (launched Jul. 2002).
Casiano-Colon, et al. “Role of the arginine deiminase system in protecting oral bacteria and an enzymatic basis for acid tolerance”, Appl. Environ. Microbiology Jun. 1988, 54(6):1318-1324.
International Search Report and Written Opinion in International Application No. PCT/US09/033305, dated Aug. 28, 2009.
Fujisawa, S. et al., “Application of bis-eugenol to a Zinc Oxide Eugenol Cement,” Journal of Dentistry 27 (1999) pp. 291-295.
Related Publications (1)
Number Date Country
20110044916 A1 Feb 2011 US
Provisional Applications (1)
Number Date Country
61027436 Feb 2008 US